No­var­tis plans for po­ten­tial ac­cel­er­at­ed ap­proval for kid­ney dis­ease drug af­ter PhI­II in­ter­im analy­sis re­sult

Last year
R&D

Deal flow in­flux: Abing­worth's new $356M fund will help Big Phar­ma ex­pand drug la­bels

Last year
Financing
Deals

GSK's Jem­per­li meets over­all sur­vival pri­ma­ry end­point in PhI­II study

Last year
R&D

Roche's $7.1B bet on Roivant drug; AD­Cs and oth­er #ES­MO23 dis­patch; High­lights from Alzheimer's con­fab; Q3 phar­ma ...

Last year
Weekly

An­oth­er Eylea threat: Roche ex­pands la­bel for block­buster eye drug Vabysmo

Last year
Pharma
FDA+

Eu­ro­pean reg­u­la­tor says ev­i­dence shows no thy­roid can­cer link to GLP-1s

Last year
Pharma
FDA+

EMA chief tells Eu­ro­pean Par­lia­ment it's no longer in cri­sis mode on pan­dem­ic, ready to han­dle short­ages

Last year
FDA+
Law

Ab­b­Vie, Genen­tech and GSK lead new phar­ma TV brand ad­ver­tis­ing in Q3 — re­port

Last year
Pharma
Marketing

CMS to kick off Medicare drug price ne­go­ti­a­tion lis­ten­ing ses­sions next week

Last year
Pharma
FDA+

Ac­cen­ture boosts life sci­ences mar­ket­ing in $245M deal for No­vo Nordisk's obe­si­ty ad agency Con­cen­tri­cLife

Last year
Deals
Pharma

As Hu­mi­ra sales fall, Ab­b­Vie fo­cus­es on Skyrizi, Rin­voq growth, eyes ex­ter­nal com­bo strate­gies 

Last year
Pharma

Re­gen­eron gives first glimpse at hear­ing loss gene ther­a­py

Last year
R&D
Cell/Gene Tx

PTC finds it­self in quag­mire of reg­u­la­to­ry set­backs, push­es back time­line on PKU treat­ment

Last year
R&D
FDA+

Ot­su­ka’s AD­HD as­set suc­ceeds in reg­is­tra­tional tri­als with chil­dren and teens

Last year
R&D

In­tas to pay €42M up­front in Hen­lius deal; Kymera gets $40M mile­stone; Plu­vic­to no longer in short sup­ply

Last year
News Briefing

FDA ques­tions off-tar­get ed­it test­ing on Ver­tex and CRISPR's po­ten­tial sick­le cell gene ther­a­py ahead of ad­comm

Last year
Cell/Gene Tx
FDA+

Sanofi shakes up clin­i­cal plans for trio of pro­grams from De­nali, Prin­cip­ia and Kymab deals

Last year
R&D
Pharma

Heard at #CPHI: VC fund­ing trends; Sam­sung eyes ex­pan­sion; and sup­ply chain di­ver­si­fi­ca­tion

Last year
Manufacturing

Flag­ship's Mon­tai Health hires first CMO; Fi­nance leader to re­tire at J&J part­ner Xen­cor

Last year
Peer Review

Prime Med­i­cine show­cas­es its first in vi­vo edit­ing da­ta in mon­keys and mice

Last year
R&D
Cell/Gene Tx

San­thera’s va­morolone bags FDA ap­proval for Duchenne af­ter long jour­ney

Last year
Pharma

Eli Lil­ly’s ul­cer­a­tive col­i­tis drug ap­proved by FDA in crowd­ed mar­ket

Last year
Pharma
FDA+

Sanofi will spin out con­sumer unit, putting weight be­hind R&D ef­forts: ‘I have to in­vest in the sci­ence now’

Last year
R&D
Pharma

Study: On­col­o­gists who take phar­ma mon­ey are more like­ly to pro­vide low-val­ue treat­ments

Last year
Pharma
FDA+
First page Previous page 255256257258259260261 Next page Last page
A service from the Financial Times